Literature DB >> 29867136

Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients.

Yan Yang1,2, Qi-Hong Wu1,2, Yan Li1,2, Ping-Jin Gao3,4,5.   

Abstract

Recent research suggested that certain small leucine-rich repeat proteoglycans (SLRPs) were involved in the development of atherosclerosis. The present study investigated the relationship between carotid atherosclerosis plaque and the circulating levels of some SLRPs, including decorin, lumican, and osteoglycin, in essential hypertension. In total, 176 essential hypertensive patients were recruited (mean age 62.1 ± 9.4, male 56.8%) in this study and were classified into two groups: patients with carotid artery plaque (n = 105, 60%) and patients without carotid artery plaque (n = 71, 40%). Patients with carotid artery plaque had higher serum concentration of lumican than patients without carotid plaque (58.0 ± 1.6 vs. 52.3 ± 2.1 ng/ml, p = 0.04) after adjusting for conventional cardiovascular risk factors. There were no differences in decorin and osteoglycin between the two groups. Multivariable logistic regression analysis revealed that lumican levels (Odds ratio (OR) per standard deviation increase, 1.598; 95% confidence interval (CI), 1.012 ~ 2.523; p = 0.04), 24-h mean systolic blood pressure (OR, 1.045; 95% CI, 1.012 ~ 1.079; p = 0.006) and the use of angiotensin receptor blocker (OR, 2.813; 95% CI, 1.023 ~ 7.734; p = 0.045) were independently associated with carotid artery plaque. Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. Circulating lumican was independently associated with carotid atherosclerosis plaque in essential hypertensive patients, indicating that SLRPs might be used as a promising molecular marker for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29867136     DOI: 10.1038/s41371-018-0077-7

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  27 in total

1.  Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency.

Authors:  M J Merrilees; B Beaumont; L J Scott
Journal:  Coron Artery Dis       Date:  2001-02       Impact factor: 1.439

2.  Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis.

Authors:  Kristin Lohr; Hardik Sardana; Seakwoo Lee; Feng Wu; David L Huso; Abdel Rahim Hamad; Shukti Chakravarti
Journal:  Inflamm Bowel Dis       Date:  2011-04-11       Impact factor: 5.325

3.  Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice.

Authors:  Ayman Al Haj Zen; Giuseppina Caligiuri; Julie Sainz; Mathilde Lemitre; Corinne Demerens; Antoine Lafont
Journal:  Atherosclerosis       Date:  2005-09-23       Impact factor: 5.162

4.  AIUM Practice Parameter for the Performance of an Ultrasound Examination of the Extracranial Cerebrovascular System.

Authors: 
Journal:  J Ultrasound Med       Date:  2016-09       Impact factor: 2.153

5.  Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis.

Authors:  Munehiko Onda; Toshiyuki Ishiwata; Kiyoko Kawahara; Ruojiao Wang; Zenya Naito; Yuichi Sugisaki
Journal:  Exp Mol Pathol       Date:  2002-04       Impact factor: 3.362

6.  Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling.

Authors:  Neeraj Vij; Luke Roberts; Sarah Joyce; Shukti Chakravarti
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

7.  Predictors of carotid thickness and plaque progression during a decade: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Matthew C Tattersall; Amanda Gassett; Claudia E Korcarz; Adam D Gepner; Joel D Kaufman; Kiang J Liu; Brad C Astor; Lianne Sheppard; Richard A Kronmal; James H Stein
Journal:  Stroke       Date:  2014-09-11       Impact factor: 7.914

8.  Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease.

Authors:  P Ranjzad; H K Salem; P A Kingston
Journal:  Gene Ther       Date:  2009-05-28       Impact factor: 5.250

9.  A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response.

Authors:  Feng Wu; Neeraj Vij; Luke Roberts; S Lopez-Briones; Sarah Joyce; Shukti Chakravarti
Journal:  J Biol Chem       Date:  2007-07-05       Impact factor: 5.157

10.  Serum Mimecan Is Associated With Arterial Stiffness in Hypertensive Patients.

Authors:  Xiaosong Gu; Liangping Zhao; Jing Zhu; Haibo Gu; Hui Li; Luchen Wang; Weiting Xu; Jianchang Chen
Journal:  J Am Heart Assoc       Date:  2015-07-23       Impact factor: 5.501

View more
  3 in total

1.  Osteoglycin and Bone-a Systematic Review.

Authors:  Jakob Starup-Linde; Rikke Viggers; Aase Handberg
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

2.  Additional Acupuncture Confers a Favorable Long-Term Prognosis for Elderly Hypertensive Patients with Carotid Atherosclerosis after Atorvastatin Treatment.

Authors:  Jiefang Li; Dan Wu; Xi Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-16       Impact factor: 2.650

3.  Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study.

Authors:  Anca Bălănescu; Ioana Florentina Codreanu; Valentina Daniela Comanici; Iustina Violeta Stan; Eugenia Bălănescu; Paul Bălănescu
Journal:  Biomed Res Int       Date:  2020-08-17       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.